Table 2.
Factors associated with reported adverse events in 228 exposed HCWs/HCSs on HIV post-exposure prophylaxis
| Characteristic | Adverse events status1 | Crude hazard ratio [95 % CI] | p-value | Adjusted hazard ratio [95 % CI] | p-value | |
|---|---|---|---|---|---|---|
| Present | Absent | |||||
| Drug regimen | ||||||
| 3TC/AZT −28 days | 68 | 7 | 1.00 | 1.00 | ||
| 3TC/AZT-3 days | 28 | 73 | 0.31 [0.20–0.48] | <0.001 | 0.30 [0.18–0.48] | <0.001 |
| 3TC/AZT/LPV-RTV-28 days | 50 | 2 | 1.06 [0.74–1.53] | 0.752 | 1.06 [0.65–1.72] | 0.817 |
| Gender | - | |||||
| Female | 81 | 50 | 1.00 | |||
| Male | 65 | 32 | 1.08 [0.78–1.50] | 0.629 | ||
| Type of exposure | - | |||||
| Percutaneous | 131 | 80 | 1.00 | |||
| Mucocutaneous | 15 | 2 | 1.42 [0.83–2.43] | 0.197 | ||
| Age category (yrs) | - | |||||
| 18–30 | 101 | 60 | 1.00 | |||
| 31–40 | 32 | 18 | 1.02 [0.69–1.52] | 0.921 | ||
| 41–50 | 8 | 2 | 1.28 [0.62–2.62] | 0.508 | ||
| >51 | 5 | 2 | 1.14 [0.46–2.80] | 0.777 | ||
| Risk assessment | ||||||
| Low | 51 | 63 | 1.00 | 1.00 | ||
| Medium | 40 | 16 | 1.60 [1.06–2.42] | 0.027 | 0.95 [0.61–1.49] | 0.885 |
| High | 55 | 3 | 2.12 [1.45–3.10] | <0.001 | 0.97 [0.57–1.66] | 0.922 |
| Profession | - | |||||
| Nurses | 51 | 31 | 1.00 | |||
| HCS | 14 | 10 | 0.94 [0.52–1.69] | 0.832 | ||
| Laboratory Staff | 15 | 1 | 1.51 [0.85–2.68] | 0.162 | ||
| Medical Doctors | 46 | 31 | 0.96 [0.65–1.43] | 0.843 | ||
| Ward Attendants | 20 | 9 | 1.11 [0.66–1.86] | 0.695 | ||
1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval